We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.28 | -0.31% | 91.02 | 90.80 | 91.02 | 91.95 | 90.81 | 91.30 | 605,355 | 16:40:00 |
From May 2022 to May 2024
By Stephen Nakrosis
Sanofi and Regeneron Pharmaceuticals Inc. said Wednesday the Food and Drug Administration approved Dupixent to treat patients with prurigo nodularis.
Dupixent, or dupilumab, is the first and only medicine specifically indicated to treat prurigo nodularis, a skin disease that can cause painful lesions, in the U.S. The companies said there are about 75,000 adults in the U.S. living with prurigo nodularis.
According to the companies, "Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials."
Dupixent has also been given regulatory approvals in one or more countries to treat certain patients with atopic dermatitis, asthma and various other ailments. More than 500,000 patients have been treated with Dupixent globally, according to the companies.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 28, 2022 18:50 ET (22:50 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
